
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
While many Danish analysts were not overly concerned by Eli Lilly's novel data for tirzepatide as a rival to Novo Nordisk's semaglutide, financial analyst Jefferies sees the new data as a considerable threat against Novo Nordisk's market shares.
Already a member? Log in.